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The NovoTTF™-100A system is a portable device that delivers intermediate frequency alternating electric fields
(TTFields, tumor treating fields) through transducer arrays arranged on the scalp. An ongoing trial is assessing its
efficacy for newly diagnosed glioblastoma multiforme (GBM) and it has been FDA-approved for recurrent GBM.
The fields are believed to interfere with formation of the mitotic spindle as well as to affect polar molecules at
telophase, thus preventing cell division. The position of the four arrays is unique to each patient and optimized
based on the patient’s imaging. We present three patients with GBM in whom the fields were adjusted at
recurrence and the effects of each adjustment. We believe there may be a higher risk of treatment failure on the
edges of the field where the field strength may be lower.
The first patient underwent subtotal resection, radiotherapy with temozolomide (TMZ), and then began NovoTTF
Therapy with metronomic TMZ. She had good control for nine months; however, new bifrontal lesions developed,
and her fields were adjusted with a subsequent radiographic response. Over the next five months, her tumor
burden increased and death was preceded by a right insular recurrence.
A second patient underwent two resections followed by radiotherapy/TMZ and NovoTTF Therapy/TMZ. Six months
later, two new distal lesions were noted, and he underwent further resection with adjustment of his fields. He
remained stable over the subsequent year on NovoTTF Therapy and bevacizumab.
A third patient on NovoTTF Therapy/TMZ remained stable for two years but developed a small, slow growing
enhancing lesion, which was resected, and his fields were adjusted accordingly. Interestingly, the pathology
showed giant cell GBM with multiple syncitial-type cells.
Based on these observations, we believe that field strength may play a role in ‘out of field’ recurrences and that
either the presence of a certain field strength may select for cells that are of a different size or that tumor cells may
change size to avoid the effects of the TTFields.
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Glioblastoma multiforme (GBM) remains a fatal disease
that affects more than 10,000 people in the United States
each year [1]. Standard therapy currently consists of surgi-
cal resection, when possible, followed by radio- and chemo-
therapy. In 2005, Stupp et al. [2] demonstrated a significant
improvement in progression-free survival at 6 months
(PFS-6) and overall survival (OS) when temozolomide, an
alkylating agent, was given during radiotherapy and for six* Correspondence: sgturner@geisinger.edu
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unless otherwise stated.months following radiation. More recently, bevacizumab, a
monoclonal antibody against VEGF, has proven effective in
treating patients with recurrent GBM [3]. Much interest ex-
ists regarding treatment options following progression on
bevacizumab, one of which is the NovoTTF-100A system,
which was FDA-approved in 2011 for adult patients with
recurrent GBM following surgery and chemotherapy [4].
This modality utilizes a novel mechanism to target tumor
cells with minimal local side effects.
Living cells contain many polar molecules that exert
and respond to electric fields. Low frequency (<1 kHz)
fields induce membrane depolarization, as seen in nerveLtd. This is an Open Access article distributed under the terms of the Creative
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generate heat and are used in radiofrequency ablation
and diathermy [5]. Low- to moderate-frequency fields
(kHz to MHz) were thought to be biologically inert,
but have been shown to cause cell rotation [6] and
alignment of microscopic particles [7]. Kirson et al. deter-
mined that intermediate-frequency alternating fields exert
these effects on tumor cells in vitro [8]. Cells become
polarized during mitosis, and dividing cells tend to ori-
ent along the direction of an externally applied field. In
addition, field intensity is increased at the cleavage furrow,
which draws polar intracellular particles toward the
furrow, which interferes with cytokinesis. At an intra-
cellular level, assembly and disassembly of microtu-
bules are disrupted in the presence of these fields due
to changes in alignment of tubulin dimers that may
prevent polymerization.
The device used with Novo TTF Therapy delivers
electric fields alternating in direction through transducer
arrays arranged on the scalp (Figure 1). Field strength,
direction, and electrode position are important to optimize
during treatment. Kirson et al. examined the effects of TTF
on several human and animal tumor types in vitro and
found that cell proliferation slowed during exposure to the
fields and that the effect was dependent on the field
frequency. The 200-kHz fields were the most cytotoxic
to rat glioma (F-98) cells. When glioma cells were im-
planted intracranially into Fischer rats and treated with
200 kHz fields, it was found that fields applied in mul-
tiple directions are optimal for cytotoxicity since cells
divide along random planes [9]. In our patients, as per
the instructions for use, we use four arrays that are po-
sitioned on the scalp based on the patient’s imaging;
these arrays deliver alternating fields along two planes
in order to maximize delivery of the electric field to the
tumor. By taking into account the different impedances of
bone, skin, brain and CSF, Kirson et el. used computerFigure 1 The NovoTTF-100A system.modeling to demonstrate the distribution of field intensity
within the brain [9]. Each patient’s magnetic resonance
imaging (MRI) is used to individualize therapy to
maximize delivery of the TTField to the region of the
tumor, while other regions of the brain receive fewer
volts per centimeter. More recently, the NovoTAL sys-
tem has been developed for investigators to calculate
the optimal placement of the electrodes on the scalp
based on each of their patient’s imaging. We present
three patients in whom the field location was adjusted
after recurrence to better treat the new lesion based on
updated imaging and the results of these adjustments.
Case presentation
Case 1
A 39-year-old woman who presented after a new-onset
seizure was found to have a left parietal GBM (genetics
not available) (Figure 2a). She underwent subtotal resection
followed by radiotherapy with daily temozolomide (TMZ),
and then NovoTTF Therapy with metronomic TMZ. After
3 months, her MRI showed progression near her initial
resection site, and temozolomide was replaced by bev-
acizumab (BEV), with NovoTTF Therapy continuing.
Nine months later, she had local recurrence in addition to
bifrontal enhancing lesions (Figure 2b), and her TTFields
were adjusted. Over the next five months, her multifocal
tumor burden increased, and death was preceded by a
right insular recurrence.
Case 2
A 41-year-old man presented after a week of intermittent
headaches and was found to have a left frontal enhancing
mass (Figure 3a). A gross total resection was performed
and the pathology showed GBM with primitive neuroec-
todermal tumor (PNET) component (MGMT promoter
unmethylated, EGFR not amplified, 1p/19q co-deletion
negative). Surgery was followed by radiotherapy and daily
TMZ and then NovoTTF therapy/metronomic TMZ. Six
months later, a distal lesion were noted (Figure 3b), and
he underwent further resection with adjustment of his fields.
In order to address the PNET component if his tumor, and
because a combination of ifosfamide, carboplatin, etoposide
(ICE) has been shown to be effective against this tumor type
[10], his chemotherapy was changed to bevacizumab with
ICE (ifosfamide, carboplatin, etoposide) × six cycles. He con-
tinued on bevacizumab with NovoTTF therapy for over a
year until he developed leptomeningeal disease and passed
away in July 2013.
Case 3
A 45-year-old man presented with headaches and was
found to have a right frontal GBM (MGMT promoter
unmethylated, EGFR not amplified, 1p/19q codeletion
status unknown) (Figure 4a), for which he had a gross total
Figure 2 Patient 1 imaging. MRI showing (a) initial left parietal
glioblastoma multiforme (GBM) and (b) bifrontal recurrence.
Figure 3 Patient 2 imaging. MRI showing (a) left frontal
glioblastoma multiforme (GBM) and (b) subsequent left parietal
recurrence (arrow).
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metronomic TMZ with NovoTTF therapy. He remained
neurologically intact with no radiographic evidence of recur-
rence for 22 months. A surveillance MRI revealed a small
enhancing lesion in the left parietal lobe (Figure 4b), which
was resected, and his fields were adjusted accordingly. The
histology of the recurrent lesion showed multiple giant
syncytial-type cells, and he has remained in good health
over the subsequent nine months.
Conclusions
Given its poor prognosis, new therapies to treat GBM are
desperately needed. The NovoTTF-100A System offers atreatment modality with minimal local side effects and no
known systemic side effects, whose efficacy is comparable
to other chemotherapy regimens [4]. In fact, combining
chemotherapy with NovoTTF therapy may improve effi-
cacy without added toxicity [11]. In order to optimize this
response, the field strength and orientation must be taken
into account; the positioning of the electrodes is based
upon the patient’s MRI in order to optimize delivery of
the field to the tumor.
Our three cases demonstrate that, when a tumor pro-
gresses locally, adjustment of the fields may lead to a
better response; however, multifocal disease is difficult
to optimally treat despite this adjustment, as seen in
Figure 4 Patient 3 imaging. MRI showing (a) initial right frontal glioblastoma multiforme (GBM) and (b) recurrent left parietal GBM which had a
giant cell component. (c) Hematoxylin and eosin (H&E) stain showing giant cells and (d) glial fibrillary acidic protein (GFAP) immunostain
(scale bar = 0.1 mm).
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remote recurrence in the second two patients may
have been due to lower field strength at these distal
sites based upon the position of the electrodes; as the
field was optimized in one location, the strength may
have been lowered elsewhere below a threshold where
newly seeded tumor cells were able to divide.
Following resection of the recurrent lesion in our third
patient, we discovered that the cells had a ‘giant-cell’
morphology, leading us to hypothesize that giant cells
avoided the toxicity of the TTFields or that existing cells
adopted this giant cell phenotype, which may require dif-
ferent parameters to achieve cytotoxicity. Indeed, Kirson
et al. [8] demonstrated that the optimal frequency for
cytotoxicity in vitro differed in various tumor cell types
and that optimal TTField frequency is inversely related to
cell size [9]. Alternately, because this patient’s recurrence
was distant from the original tumor site, the potentially
decreased field strength may have also contributed to the
recurrence, as we hypothesized for our other patients.
In addition to differences in TTField strength within
the brain, other factors may be associated with distant
recurrence including radiation field strength and genetic
profile. Brandes et al. [12] found that, in 79 patients
with recurrent GBM treated with radiation plus daily
TMZ followed by metronomic TMZ, distant recur-
rence (outside the radiation field) occurred in 21.5% of
patients, while recurrence within or at the radiother-
apy margin occurred in 85% of patients with MGMTunmethylated promoters and 57.9% of patients with
MGMT methylated promoters. Why distant recurrence
should be associated with MGMT promoter methylation
is not known but may be due to changes in cell motility
patterns or the fact that the combination of radiation and
temozolomide act synergistically on cells with MGMT
promoter methylation, thus reducing the likelihood of
local recurrence. All three patients presented here had
recurrence outside their initial radiation treatment
fields, and though genetics are not available for our
first patient, the second two patients had unmethylated
MGMT promoters and would therefore be thought less
likely to recur distally, according to the findings described
by Brandes et al.
Treatment with anti-angiogenic agents should also be
taken into account when considering distal GBM recur-
rence. Bevacizumab has been shown to induce a more
invasive phenotype in vitro and in vivo, perhaps by up-
regulating expression of matrix metalloproteinases [13]. In
addition, clinical studies [14,15] have found that treatment
with bevacizumab is associated with an increased incidence
of distal recurrence. This may be due to genetic alterations
that effect a more invasive phenotype, allowing cells to
migrate along normal blood vessels or within the extra-
cellular matrix in order to escape a hypoxic microenvir-
onment [16]. The recurrences described in the first two
patients presented here should therefore be considered
in light of their treatment with bevacizumab. Further
study is clearly warranted in order to better understand the
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tailor them to specific tumor cell sizes and types.
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